This approval follows the CDE’s clearance in July of this year for Phase 2/3 clinical studies of CB03-154 in amyotrophic lateral sclerosis
Accro will retain global rights to develop, manufacture, and commercialize AC-201 (excluding Chinese Mainland, Hong Kong SAR, and Macau SAR)
SUP will obtain regulatory approvals for selling Tiotropium DPI in China
Record international participation reflects renewed momentum in pharma manufacturing and global sourcing, as easing tariffs fuel growth
3SBio will receive an upfront payment of $1.25 billion and is eligible to receive milestone payments associated with certain development, regulatory and commercial milestones up to $4.8 billion
This approval authorizes the company to export Ibuprofen to the Chinese markets
This marks a significant milestone in Morepen’s strategic entry into one of the world’s largest pharmaceutical markets
Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai
Around 100 million people live with COPD in China, accounting for almost 25% of all COPD cases globally
In 2020, CORXEL acquired the rights to develop and commercialize aficamten in Greater China
Subscribe To Our Newsletter & Stay Updated
